White House pulls Trump’s nomination for CDC director hours before confirmation hearing

White House pulls Trump’s nomination for CDC director hours before confirmation hearing


Former Congressman Dave Weldon addresses a small crowd in The Villages, Fla.

Brendan Farrington | AP

The White House has pulled President Donald Trump’s nominee to lead the Centers for Disease Control and Prevention, former Rep. Dave Weldon, the Senate’s Health committee confirmed Thursday.

The move came just hours before the former Florida lawmaker, a vaccine critic, was set to appear before the U.S. Senate Committee on Health, Education, Labor and Pensions for a confirmation hearing.

Axios first reported the decision on Thursday. Robert F. Kennedy, who leads the Department of Health and Human Services, said Weldon wasn’t ready for the role, Axios reported. HHS oversees the CDC and all other federal health agencies.

But Weldon’s views align closely with Kennedy, a notorious vaccine skeptic. Weldon, 71, has long questioned the safety of certain vaccines, promoting the false claim linking vaccines to autism. In 2006, Weldon appeared with parents who claimed that the CDC had covered up evidence tying vaccines to children developing autism.

The CDC will reportedly re-examine that link under Kennedy despite decades of research debunking it.

While in Congress, Weldon sponsored a bill that would transfer responsibility for vaccine safety away from the CDC. He claimed the agency had a conflict of interest because it purchases and promotes vaccines. The bill never made it past committees. 

Weldon is an internal medicine doctor who served in Congress for 14 years, from 1995 to 2009. 

This story is developing. Please check back for updates.



Source

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Health

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020. Mike Blake | Reuters Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 […]

Read More
Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval
Health

Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in […]

Read More
Eli Lilly earnings are coming Thursday. Here’s what top analysts expect
Health

Eli Lilly earnings are coming Thursday. Here’s what top analysts expect

Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and […]

Read More